Featured Research

from universities, journals, and other organizations

Chronic Kidney Disease Should Not Prevent Women From Taking The Osteoporosis Drug Raloxifene, Study Suggests

Date:
April 9, 2008
Source:
American Society of Nephrology
Summary:
The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease, according to a new study. The findings indicate that raloxifene is safe and effective for women with CKD, a patient population often excluded from studies of osteoporosis drugs.

The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease (CKD), according to a new study. The findings indicate that raloxifene is safe and effective for women with CKD, a patient population often excluded from studies of osteoporosis drugs.

Because CKD may lead to metabolic abnormalities that accelerate bone loss, it is important to monitor bone mineral density levels in these patients and to administer treatments when levels are low. However, the use of osteoporosis therapies for patients with this disease is highly controversial, given the drugs' previously unknown effectiveness and safety in these individuals.

To determine whether raloxifene is a suitable treatment option for women with CKD, Dr. Areef Ishani, of the Minneapolis VA Medical Center and University of Minnesota, in Minneapolis, MN, and his colleagues analyzed data from the Multiple Outcomes of Raloxifene Evaluation (MORE), a multi-center, randomized, placebo-controlled trial of 7,705 postmenopausal women with osteoporosis. They examined the effect of raloxifene over three years on the rate of change of bone mineral density, incidence of fractures, and adverse effects in women with and without CKD.

The investigators found that irrespective of kidney function, patients taking raloxifene experienced a greater increase in spine bone mineral density and a reduction in vertebral fractures compared with patients taking a placebo. Raloxifene also increased hip bone mineral density, most prominently in women with mild to moderate CKD.

The study's results have significant clinical relevance because many postmenopausal women have unidentified CKD. The findings are reassuring in that raloxifene can safely be used in women who have decreased kidney function.

The study, entitled, "The Effect of Raloxifene Treatment in Postmenopausal Women with CKD," will be available online beginning April 9, 2008 at the website of the Journal of the American Society Nephrology. It will be published in the July 2008 issue.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Cite This Page:

American Society of Nephrology. "Chronic Kidney Disease Should Not Prevent Women From Taking The Osteoporosis Drug Raloxifene, Study Suggests." ScienceDaily. ScienceDaily, 9 April 2008. <www.sciencedaily.com/releases/2008/04/080409120622.htm>.
American Society of Nephrology. (2008, April 9). Chronic Kidney Disease Should Not Prevent Women From Taking The Osteoporosis Drug Raloxifene, Study Suggests. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2008/04/080409120622.htm
American Society of Nephrology. "Chronic Kidney Disease Should Not Prevent Women From Taking The Osteoporosis Drug Raloxifene, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/04/080409120622.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins